2216 logo

Broncus Holding Stock Price

Symbol: SEHK:2216Market Cap: HK$1.7bCategory: Healthcare

2216 Share Price Performance

Community Fair Values

    Recent 2216 News & Updates

    No updates

    Broncus Holding Corporation Key Details

    US$8.1m

    Revenue

    US$2.0m

    Cost of Revenue

    US$6.1m

    Gross Profit

    US$21.4m

    Other Expenses

    -US$15.3m

    Earnings

    Last Reported Earnings
    Dec 31, 2024
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -0.029
    Gross Margin
    75.50%
    Net Profit Margin
    -188.21%
    Debt/Equity Ratio
    0.01%

    Broncus Holding Corporation Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About 2216

    Founded
    2012
    Employees
    200
    CEO
    Hong Xu
    WebsiteView website
    www.broncus.com

    Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, and thoracic surgery staining location; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China.

    Chinese Market Performance

    • 7 Days: 1.4%
    • 3 Months: 12.7%
    • 1 Year: 30.0%
    • Year to Date: 13.1%
    The market has climbed 1.4% in the last 7 days, lead by the Information Technology sector with a gain of 4.0%. The market is up 30% over the last 12 months. Looking forward, earnings are forecast to grow by 23% annually. Market details ›
    Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
    Continue reading